Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

971
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
971
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

929
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
929
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

886
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
886
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

340
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
340
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

319
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
319

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Country-specific differences in the association between obesity risk factors in two high-income countries: a cross-sectional analysis from the Prospective Urban Rural Epidemiology (PURE) study.

BMC public health·2026
Same author

Life-course trajectories and modifiable risk factors for incident walking limitation and mortality in 25 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.

The lancet. Healthy longevity·2026
Same author

Pre-pregnancy weight in Swedish women and the risk of gestational diabetes and subsequent type 2 diabetes-a population-based cohort study.

EClinicalMedicine·2026
Same author

Heart Failure Among 173,000 Community-Dwelling Participants From 25 Low-, Middle-, and High-Income Countries in the PURE Study.

Journal of the American College of Cardiology·2026
Same author

The demands-control-support work stress model and risk of ischemic heart disease: causal inference based on observational epidemiology.

Scandinavian journal of work, environment & health·2026
Same author

Pharmacological treatment after a first myocardial infarction in Sweden - long-term adherence and prognosis.

European heart journal. Quality of care & clinical outcomes·2026

Related Experiment Video

Updated: Feb 4, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

Decrease in loop diuretic treatment from 2005 to 2014 in Swedish real-life patients with chronic heart failure.

Pär Parén1,2, Annika Rosengren3,4, Tatiana Zverkova Sandström3

  • 1Department of Internal Medicine, Sahlgrenska University Hospital/Mölndal, S-431 80, Mölndal, Sweden. par.paren@vgregion.se.

European Journal of Clinical Pharmacology
|October 16, 2018
PubMed
Summary

Loop diuretic use in heart failure patients decreased nationwide from 2005 to 2014. Doses also declined, but the impact on patient outcomes requires further investigation.

Keywords:
Heart failureOutpatientsPharmaco-epidemiology

More Related Videos

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K
Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.4K

Related Experiment Videos

Last Updated: Feb 4, 2026

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K
Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
07:41

Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension

Published on: March 17, 2022

3.4K

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Loop diuretics are standard for heart failure symptom management.
  • Observational studies link loop diuretics to increased mortality in heart failure patients.
  • Clinical guidance suggests reducing or discontinuing loop diuretics when feasible.

Purpose of the Study:

  • To analyze national trends in loop diuretic treatment for chronic heart failure patients.
  • To examine temporal changes in loop diuretic prescription patterns from 2005 to 2014.

Main Methods:

  • Utilized nationwide Swedish registers (Patient, Prescribed Drug, Cause of Death).
  • Calculated annual proportions of chronic heart failure patients receiving loop diuretics.
  • Determined annual median loop diuretic doses (DDD) for treated patients.

Main Results:

  • Loop diuretic treatment decreased from 73.2% in 2005 to 65.7% in 2014.
  • Median loop diuretic DDD declined from 2.13 to 1.63 between 2005 and 2014.
  • Both trends showed statistical significance (p < 0.001 for proportion, p = 0.001 for DDD).

Conclusions:

  • Loop diuretic utilization in chronic heart failure patients showed a significant decline between 2005 and 2014.
  • The clinical significance and prognostic implications of these treatment trends remain uncertain.